These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18627324)

  • 1. A strategy for developing effective amyotropic lateral sclerosis pharmacotherapy: from clinical trials to novel pharmacotherapeutic strategies.
    Yamamoto M; Tanaka F; Tatsumi H; Sobue G
    Expert Opin Pharmacother; 2008 Aug; 9(11):1845-57. PubMed ID: 18627324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment.
    Goodall EF; Morrison KE
    Expert Rev Mol Med; 2006 May; 8(11):1-22. PubMed ID: 16723044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic advances in amyotrophic lateral sclerosis.
    Louvel E; Hugon J; Doble A
    Trends Pharmacol Sci; 1997 Jun; 18(6):196-203. PubMed ID: 9226998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein disulphide isomerase protects against protein aggregation and is S-nitrosylated in amyotrophic lateral sclerosis.
    Walker AK; Farg MA; Bye CR; McLean CA; Horne MK; Atkin JD
    Brain; 2010 Jan; 133(Pt 1):105-16. PubMed ID: 19903735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Research in amyotrophic lateral sclerosis: what is new in 2009?].
    Pradat PF; Attarian S; Camdessanché JP; Carluer L; Cintas P; Corcia P; Echaniz-Laguna A; Gonzalez-Bermejo J; Guy N; Nicolas G; Perez T; Soriani MH; Vandenberghe N; Verschueren A;
    Rev Neurol (Paris); 2010; 166(8-9):683-98. PubMed ID: 20472259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of involvement of neuronal nitric oxide synthase in the pathogenesis of a transgenic mouse model of familial amyotrophic lateral sclerosis.
    Facchinetti F; Sasaki M; Cutting FB; Zhai P; MacDonald JE; Reif D; Beal MF; Huang PL; Dawson TM; Gurney ME; Dawson VL
    Neuroscience; 1999; 90(4):1483-92. PubMed ID: 10338314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyotrophic lateral sclerosis models derived from human embryonic stem cells with different superoxide dismutase 1 mutations exhibit differential drug responses.
    Isobe T; Tooi N; Nakatsuji N; Aiba K
    Stem Cell Res; 2015 Nov; 15(3):459-468. PubMed ID: 26413785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis.
    Kaur SJ; McKeown SR; Rashid S
    Gene; 2016 Feb; 577(2):109-18. PubMed ID: 26657039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neurobiology of amyotrophic lateral sclerosis.
    Bento-Abreu A; Van Damme P; Van Den Bosch L; Robberecht W
    Eur J Neurosci; 2010 Jun; 31(12):2247-65. PubMed ID: 20529130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex genetics of amyotrophic lateral sclerosis.
    Kunst CB
    Am J Hum Genet; 2004 Dec; 75(6):933-47. PubMed ID: 15478096
    [No Abstract]   [Full Text] [Related]  

  • 11. Amyotrophic lateral sclerosis: drug therapy from the bench to the bedside.
    Gibson SB; Bromberg MB
    Semin Neurol; 2012 Jul; 32(3):173-8. PubMed ID: 23117941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catalytic antioxidants to treat amyotropic lateral sclerosis.
    Crow JP
    Expert Opin Investig Drugs; 2006 Nov; 15(11):1383-93. PubMed ID: 17040198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing amyotrophic lateral sclerosis: slowing disease progression and improving patient quality of life.
    Brooks BR
    Ann Neurol; 2009 Jan; 65 Suppl 1():S17-23. PubMed ID: 19191306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. System xC- is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice.
    Mesci P; Zaïdi S; Lobsiger CS; Millecamps S; Escartin C; Seilhean D; Sato H; Mallat M; Boillée S
    Brain; 2015 Jan; 138(Pt 1):53-68. PubMed ID: 25384799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of amyotrophic lateral sclerosis - what is the next step?
    Ludolph AC
    J Neurol; 2000 Dec; 247 Suppl 6():VI/13-8. PubMed ID: 19714403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "True" sporadic ALS associated with a novel SOD-1 mutation.
    Alexander MD; Traynor BJ; Miller N; Corr B; Frost E; McQuaid S; Brett FM; Green A; Hardiman O
    Ann Neurol; 2002 Nov; 52(5):680-3. PubMed ID: 12402272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of amyotrophic lateral sclerosis--what is the next step?
    Ludolph AC
    J Neurol; 2000 Dec; 247():13-8. PubMed ID: 11200700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.
    Mackenzie IR; Bigio EH; Ince PG; Geser F; Neumann M; Cairns NJ; Kwong LK; Forman MS; Ravits J; Stewart H; Eisen A; McClusky L; Kretzschmar HA; Monoranu CM; Highley JR; Kirby J; Siddique T; Shaw PJ; Lee VM; Trojanowski JQ
    Ann Neurol; 2007 May; 61(5):427-34. PubMed ID: 17469116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model.
    Waibel S; Reuter A; Malessa S; Blaugrund E; Ludolph AC
    J Neurol; 2004 Sep; 251(9):1080-4. PubMed ID: 15372249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Difficulties in distinguishing sporadic from familial amyotrophic lateral sclerosis.
    Orrell RW; Habgood J; Rudge P; Lane RJ; de Belleroche JS
    Ann Neurol; 1996 Jun; 39(6):810-2. PubMed ID: 8651656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.